文献速递骨质疏松与钙磷/甲状旁腺肥胖与代谢综合征

地舒单抗在接受雌二醇抑制的绝经前乳腺癌女性中的心脏代谢效应:随机对照试验

Cardiometabolic Effects of Denosumab in Premenopausal Women With Breast Cancer Receiving Estradiol Suppression: RCT.
PubMed 文献 · J Clin Endocrinol Metab · 2024-01-01

这项12个月随机双盲安慰剂对照试验的预设二次分析纳入68例开始卵巢功能抑制和芳香化酶抑制的绝经前乳腺癌女性,随机接受地舒单抗60 mg或安慰剂(基线和6个月给药)。与安慰剂相比,地舒单抗组腹部和臀部脂肪量下降,总脂肪量和腰围有降低趋势但未达统计学显著,其他体成分和代谢指标无显著治疗效应。

要点

  • 地舒单抗组腹部脂肪量较安慰剂组降低266 g(95%CI -453至-79,P=0.02)。
  • 地舒单抗组臀部脂肪量较安慰剂组降低452 g(95%CI -783至-122,P=0.03)。
  • 瘦体重、BMI、空腹血糖、HOMA-IR和血脂谱未见显著治疗效应。

核心结论

  • 在接受雌二醇抑制的绝经前乳腺癌女性中,地舒单抗降低部分脂肪量指标,但对其他体成分指标或代谢参数未检测到效应。

研究设计与样本

  • 12个月随机双盲安慰剂对照试验的预设二次分析,纳入68例开始卵巢功能抑制和芳香化酶抑制的绝经前乳腺癌女性。
  • 受试者随机接受地舒单抗60 mg或安慰剂,在基线和6个月给药。

主要发现

  • 与安慰剂相比,地舒单抗组腹部脂肪量降低266 g(95%CI -453至-79,P=0.02),臀部脂肪量降低452 g(95%CI -783至-122,P=0.03)。
  • 地舒单抗组总脂肪量较安慰剂组降低1792 g(95%CI -3346至-240,P=0.08),未达统计学显著。
  • 地舒单抗组腰围较安慰剂组降低3.77 cm(95%CI -6.76至-0.79,P=0.06),未达统计学显著。
  • 瘦体重、BMI、臀围、空腹血糖、HOMA-IR和血脂谱未见显著治疗效应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Menopause is associated with changes in musculoskeletal, body composition, and metabolic parameters that may be amplified in premenopausal women receiving estradiol suppression for breast cancer. Denosumab offsets deleterious skeletal effects of estradiol suppression and has been reported to have effects on body composition and metabolic parameters in preclinical and observational studies, but evidence from double-blind randomized controlled trials is limited. OBJECTIVE: To assess the effect of denosumab on body composition and metabolic parameters. METHODS: In a prespecified secondary analysis of a 12-month randomized, double-blind, placebo-controlled trial, 68 premenopausal women with breast cancer initiating ovarian function suppression and aromatase inhibition were randomized to denosumab 60-mg or placebo administered at baseline and 6 months. Outcome measures were total and regional fat and lean mass (DXA), body mass index (BMI), waist and hip circumference, fasting glucose, HOMA-IR, and lipid profile. Using a mixed model, between-group mean adjusted differences over time are reported. RESULTS: Over 12 months, relative to placebo, android and gynoid fat mass decreased in the denosumab group (-266 g [95% CI -453 to -79], P = .02, and -452 g [-783 to -122], P = .03, respectively). Total fat mass and waist circumference were lower in the denosumab group but not significantly (-1792 g [-3346 to -240], P = .08 and (- 3.77 cm [-6.76 to -0.79], P = .06, respectively). No significant treatment effects were detected in lean mass, BMI, hip circumference, fasting glucose, HOMA-IR, or lipid profile. CONCLUSION: In premenopausal women receiving estradiol suppression, denosumab decreases some measures of fat mass with no detectable effects on other measures of body composition or metabolic parameters.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Ramchand SK, Hoermann R, White S, et al. Cardiometabolic Effects of Denosumab in Premenopausal Women With Breast Cancer Receiving Estradiol Suppression: RCT. J Clin Endocrinol Metab. 2024. PMID: 38181438. doi:10.1210/clinem/dgae003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。